INTRODUCTION AND OBJECTIVES: Docetaxel (DTX) is one of the primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to DTX therapy and their disease will continue to progress. The mechanisms by which resistance develops is still incompletely understood. This study seeks to determine the involvement of miRNAs, specifically miR-181a, in DTX resistance in CRPC.
METHODS: Total RNA from parental C4-2B prostate cancer cells and DTX resistant C4-2B cells (C4-2B TaxR) was submitted for small RNA deep sequencing. Data was analyzed to ascertain which miRNAs expressions were most altered in C4-2B TaxR cells compared to parental cells. Having identified an increase in miR-181a in resistant cells, its expression was modulated in C4-2B and C4-2B TaxR cells by transfecting them with miR-181a mimics or antisense, respectively. Following transfection, cell number was determined after 48 h with or without DTX. Cross resistance to cabazitaxel induced by miR-181a was also determined. Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity. Phospho-p53 expression was assessed by western blot and apoptosis was measured by ELISA in C4-2B TaxR cells with inhibited miR-181a expression with or without DTX.
RESULTS: miR-181a is significantly upregulated in C4-2B TaxR cells compared to parental C4-2B cells as analyzed by small RNA sequencing. Overexpression of miR-181a in C4-2B cells confers DTX and cabazitaxel resistance. Knockdown of miR-181a in C4-2B TaxR cells re-sensitizes them to treatment with both DTX and cabazitaxel. miR-181a knockdown alone induced apoptosis in C4-2B TaxR cells which is further enhanced by DTX. We next assessed if miR-181a altered expression or activity of ABCB1, which is overexpressed/active in C4-2B TaxR cells and promotes resistance to DTX by pumping the drug out of cells. We found that miR-181a does not impact ABCB1 expression or activity. Since we previously demonstrated that phospho-p53 can modulate DTX sensitivity, we determined if miR-181a can alter p53 expression in C4-2B TaxR cells. Knockdown of miR-181a in C4-2B TaxR cells induced phospho-p53 expression, suggesting that miR-181a induced resistance to DTX is mediated by inhibition of phospho-p53 expression.
CONCLUSIONS: Overexpression of mir-181a in C4-2B TaxR cells contributes to their resistance to DTX and inhibition of mir-181a expression can restore treatment response. This is due, in part, to modulation of p53 phosphorylation and induction of apoptosis.
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This work is supported in part by grants NIH/NCI This work was supported in part by grants NIH/NCI CA140468, CA168601, CA179970, and DOD PCRP PC150040. (PCa) is the most common cancer diagnosed in males and the second leading cause of death from cancer in men. Despite the advances in cancer therapy, when PCa progress to castration resistant phase, patients develop incurable bone metastases. Therefore, understanding of the processes that regulate homing and survival of metastatic cancer cells in the bone is crucial for the identification of new therapies. TGF-b signaling plays a major role in bone remodeling and according to the 00 vicious cycle hypothesis 00 is a master regulator of maintenance of prostate cancer cells in lytic bone lesions. microRNAs (miRs) are a class of small non-coding RNAs that regulates many biological process. miR-221 expression has been previously associated with prostate cancer progression. Here we studied the effect of miR-221 on TGF-b signaling and the impact of miR-221 on tumor growth in vivo.
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METHODS: miR-221 was overexpressed in PC3 and RWPE-1 cells and PMEPA was monitored by RT-qPCR and western blot. Expression of miR-221 in PC3 and RWPE-1 cells was assessed by RT-qPCR. Predicted targets were identified in silico (Targetscan and microRNA.org). Luciferase assay was used to investigate the interaction between miR-221 and PMEPA1. For zebrafish experiment, fluorescently labelled PC-3M-Pro4 cells overexpressing miR-221 were injected in the duct of cuvier of zebrafish embryos.
RESULTS: We found that miR-221 overexpression resulted in decreased PMEPA1 mRNA and protein in PC-3 human prostate cancer cells. PMEPA1 is a master regulator of TGF-b signaling and luciferase reporter assay revealed that miR-221 can directly interact with PMEPA1 3 0 UTR. Our experiments showed an enhancement of the proliferative effect of TGF-b in PC-3 cells, following enforced miR-221 expression. In conclusion, we observed increased Smad2 activation upon TGF-b treatment in miR-221 overexpressing PC-3 cells. Inoculation of fluorescently labelled highly metastatic PC-3M-Pro4 cells overexpressing miR-221 in the Duct of Cuvier (DC) of zebrafish embryos resulted reduced tumor burden compared to control. Finally, we found an inverse correlation between miR-221 and PMEPA1 expression in normal vs. tumor tissue collected from PCa patients.
CONCLUSIONS: Our results indicate that miR-221 is a regulator of TGF-b signaling via modulation of PMEPA1 and miR-221 overexpression can reduce tumor growth in vivo. Therefore, miR-221 represents an interesting molecule to target PCa and to interfere with the maintenance of PCa cells in the bone microenvironment. RESULTS: circRNA17 (hsa_circ_001305) has a lower expression in C4-2 Enz-resistant cells compared to that in C4-2 parental cells. Knocking down circRNA17 in C4-2 parental cells increased the expression of ARv7 that resulted in decreased sensitivity to Enz and increased cell invasion.
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CONCLUSIONS: circRNA17 can alter the Enz sensitivity and cell invasion in CRPC cells via modulating the miR-181c-5p-ARv7 signaling and targeting this newly identified signaling may help us to develop a better therapy to further suppress the CRPC. is a common mutation in human cancers, its functional annotation is limited to studying myelocytomatosis (MYC), the prominent oncogene in the amplicon. However, MYC is co-gained with an adjacent long noncoding RNA gene plasmacytoma variant translocation 1 (PVT1), CCDC26 and gasdermin C (Gsdmc). Whether copy number gain of one or more of these genes drives neoplasia is unknown.
METHODS: We developed chromosome engineered mouse strains with an extra copy of 1) Myc, 2) Pvt1, Ccdc26, Gsdmc, and 3) Myc, Pvt1, Ccdc26, Gsdmc. These mice were crossed with transgenic mice harboring rat Neu was introduced to test the change in the latency in mammary tumor development. We also used genetically engineered human cancer cell lines to identify the molecular basis of co-operation between MYC and PVT1 in human cancer.
RESULTS: Only the mice with an extra copy of Myc, Pvt1, Ccdc26, Gsdmc developed adenocarcinomas, suggesting that may cooperate with Pvt1, Ccdc26 or Gsdmc to promote cancer. Si-RNA mediated knockdown of Pvt1/PVT1 reduced the proliferation rates in the tumors. Ablation of PVT1 decreased MYC protein levels, suggesting a PVT1-dependence of MYC protein in MYC amplified cancer cells.
